Kuur Therapeutics: Advancing Anti-Cancer CAR-NKT Cell Therapies

Discussion

Kuur Therapeutics Ltd is actually committed to changing and transforming the particular lives of the patients having cancer. It should be noted that Kuur has been leading the progression and development in relation to the off-the-shelf ‘engineered CAR-NKT cell therapies’. The approach of the Kuur Therapeutics combines or amalgamates the highly distinguished, natural biology in relation to any particular subset of the cytotoxic T cells, known as the ‘natural killer T’ cells (or the NKT cells) and the innovative or pioneering CAR construct engineering. In the combination or amalgamation, this actually provides a very unique and compelling platform, which is believed to have the potential of producing numerous future therapies that actually targets the solid as well as the hematological tumors (kuurtx.com 2022).

Cell Medica (which is based in Houston) has re-branded itself by adopting the name ‘Kuur Therapeutics’. Such re-branding had been done in order to dive into the progression and development of the anti-cancer treatments and therapies through the utilization of its innovative and ground-breaking ‘chimeric antigen receptor natural killer T’ cell (or the CAR-NKT) therapy stand or platform (Meyer et. al. 2020). As the above said company goes on board with its new business, it is hugely dependent upon the financial assistance or support and investments from the Baylor College of Medicine (or BCM), Schroeder Adveq and IP Group (Baird et. al. 2020). The company has actually planned to utilize the financial support to provide support and assistance in respect of 2 Phase I studies, which includes the GINAKIT 2 (that explores the autologous ‘CAR-NKT’ cells in the neuroblastoma) and the ANCHOR (that assesses the allogeneic ‘CAR-NKT’ cells in the ‘CD19’ malignancy). The funding and capital shall also provide support in respect of the preclinical progression and development of a specific allogeneic ‘CAR-NKT’ product for the purposes of the treatment of the hepatocellular carcinoma, prior to an IND submission that is expected in 1H 2021 (kuurtx.com 2022).

The novel and fresh CAR-NKT platform of Kuur Therapeutics can be said to be a next-generation technology and know-how of the engineered immune cells having enhanced operations for the purposes of the treatment of the solid and the hematological tumors. The ‘CAR-NKT’ cells of Kuur Therapeutics have been concocted and engineered in order to secrete the IL-15 for prolonging persistence as well as enhancing anti-tumor activity (Quach et. al. 2020).

The primary aim of this report is to deliver the strategic issues, the challenges, the solutions, the implementation as well as the recommendations in relation to the above said company named Kuur Therapeutics Ltd.

Strategic Issues

Annalisa Jenkins (the chairperson of the board of directors of Kuur Therapeutics) called Kevin S. Boyle (the new CEO of the above said company) to be a ‘change agent’, who shall lead or spearhead the company throughout a decisive and vital period. She mentioned that Boyle shall be influential in the securing of the additional funding and sponsoring for the above said company in order to advance the lead ‘CAR-NKT’ products/commodities through the clinic. It should be noted that Kevin S. Boyle has actually been successful in raising more than $2 billion in the equity and the debt capital.

In this regard, the SWOT analysis shall be used in order to find out and understand the strategic issues. A ‘strengths, weaknesses, opportunities, and threats’ (SWOT) analysis of Kuur Therapeutics shall reveal the observations mentioned below: –

• Kuur Therapeutics ltd can be said to have an established and a developed pharmaceutical industry along with a proper manufacturing base as well as ability to produce the quality drugs. 
• Kuur Therapeutics has a pool of proficient and productive alumni, who are hard working as well as flexible.
• The facilities at Kuur Therapeutics have been designed and structured in line with the European Union cGMP necessities, and regular inspections are conducted at the locations.
• The employees of Kuur Therapeutics are well educated, English spoken as well as multilingual (com 2022).
• Kuur Therapeutics is a part of ‘Pharmaceutical and Medicine Manufacturing Industry’ in London.
• The above said company can be said to be a leading research organization in connection to the CAR-NKT cell therapies for combatting the solid as well as the hematological tumors (businesswire.com 2022).

• There have been limitations in connection to the 1^stgeneration of the cell therapy treatments that are focused or attentive upon the autologous CAR-T.
• The development or progression of the innovative therapies at the Kuur Therapeutics have been decelerating in the recent years due to lack of experienced team and extensive.

• The Government of United Kingdom enables Kuur Therapeutics by offering them the potential to combine and merge the knowledge in relation to the pharmaceutical industry with biotechnology and biopharmaceutical industry. 
• The United Kingdom possesses a free-market economyand the Internal Market of United Kingdom has been the foundation of the shared prosperity with products and people, and hence, Kuur Therapeutics shall be able to enjoy such market.
• The regulatory framework is good and the country embraces the mutual recognition agreement.
• Financial assistance as well investment tax credits are actually present for Kuur Therapeutics in the arrangements of guarantees, interest subsidies and soft loans from the enterprises such as Baylor College of Medicine (or BCM), Schroeder Adveq and IP Group.
• The United Kingdom consists of an encouraging political, social and legal climate as well as striking low corporation tax that holds the tax imputation structure, and all these features are actually beneficial for Kuur Therapeutics.
• United Kingdom can be considered to be a strategic gateway and hub to continental Europe as well as the Middle East and the Euro-Mediterranean region, and hence, such strategic structure is certainly beneficial for Kuur Therapeutics.
• Sound financial facilities are certainly available for Kuur Therapeutics that enables the company in swift rebound from any kind of global economic turmoil.
• Good and safe quality lifestyle along with the cultural heritage is always helpful, as in the case of Kuur Therapeutics (com 2022).

• Competition from the other developing nations is certainly increasing.
• The investment and infrastructure in relation to research and development are not up to the mark in all the instances.
• The storage facilities and the transport infrastructures for the specific temperature-sensitive drugs and medications are not always readily available (com 2022).

The challenges that are faced by Kuur Therapeutics have been discussed below: –

Limitation Regarding Development

The first challenge is that in the case of Kuur Therapeutics, there have been limitations in connection to the 1^st generation of the cell therapy treatments that are focused or attentive upon the autologous CAR-T. It should be noted that the development or progression of the innovative therapies at the Kuur Therapeutics have been decelerating in the recent years due to lack of experienced team and extensive (ipgroupplc.com 2022). The investment and infrastructure in relation to research and development in Kuur Therapeutics are not up to the mark in all the instances. The storage facilities and the transport infrastructures for the specific temperature-sensitive drugs and medications are not always readily available, and due to such unavailability, numerous problems are actually faced by Kuur Therapeutics. Due to such challenges and shortcomings, discussions have been ongoing that Athenex may acquire Kuur Therapeutics in order to expand the development of cell therapy with the particular engineered ‘CAR-NKT’ platform (techmap.uh.edu 2022). Even though the invention regarding cell therapy by Kuur Therapeutics has been ground breaking, the resources that would be mandatory for development and progression in such field, are not present with the company. Therefore, Athenex wishes to combine its TCR program with the unique and ground breaking ‘NKT’ cell platform that have been developed at the Texas Children’s Hospital and the Baylor College of Medicine (BCM) by Professor Leonid Metelitsa. Athenex are pretty confident and self-assured that they shall be able to continue the innovation in relation to the NKT cell platform (fiercebiotech.com 2022). Kuur Therapeutics shall only provide any specific solution or explanation that might address few of the known drawbacks or limitations in connection to the 1^st generation regarding the cell therapy treatments that are focused upon the autologous CAR-T. The officials at Athenex seek to change cancer into any chronic disease. However, such confidence or self-assurance cannot be perceived in case of Kuur Therapeutics (pharmaceutical-business-review.com 2022).

Strengths

The allogeneic cell therapy actually possesses the capacity to be less expensive as well as much faster in comparison to the patient-specific autologous commodities or products, and the NKT cells actually offer numerous advantages over the other cell kinds for the allogeneic immunotherapy applications. However, it must be noted that Kuur Therapeutics does not have the required resources to continue the development regarding the same. The primary objective of Kuur Therapeutics has been to improve the ability of the NKT cells so that they are able to attack the solid and hematological tumors. However, the development regarding the same has been stagnated due to the unavailability of the necessary resources (Martin 2022).

Competition

Competition can be said to be a primary challenge that is being faced by Kuur Therapeutics. The main competitors of Kuur Therapeutics include ImmunoScape, PrimeVax Immuno-Oncology, Sandhill Therapeutics and Ossium Health. ImmunoSCAPE can be said to be a company or organization that actually measures the treatment as well as the outcome-associated alterations or changes in the antigen-specific T cells. It also concerns itself with the patient immune response. PrimeVax Immuno-Oncology can be said to be an organization that helps to develop a multi-mechanism treatment in relation to cancer, leveraging the entire body systemic fever with the personalized neo-antigens (Abou-el-Enein et. al. 2021). Sandhill Therapeutics can be said to be a company that provides treatment in relation to cancer. And ultimately, Ossium Health can be said to be an organization that is involved in the building of the bone marrow bank in order to treat the blood cancers, improve the organ transplantation, as well as repair the damage from the radiation. Hence, it can be understood that all the companies mentioned above, are actively involved in the development and progression of the cell therapy (Mo et. al. 2021).

KUR-502 has been built on the next-generation ‘CAR-NKT’ platform of Kuur Therapeutics, with the novel engineering abilities that harness as well as enhance the exclusive tumor-homing characteristics of the NKT cells. This particular NKT platform technology had been developed in CAGT Laboratory of Dr. Leonid Metelitsa (who can be said to be the Professor of the subject of Pediatrics-Oncology at Texas Children’s Hospital and Baylor College of Medicine or BCM, as well as member of ‘Dan L Duncan Comprehensive Cancer Center’) and KUR-502 had also been produced by CAGT cGMP facility. In this regard, a primary challenge that has been faced by Kuur Therapeutics is that infusing any patient with the donor-consequent lymphocytes may tempt the ‘graft versus host disease’ (or GvHD), which is actually a possibly life-threatening disorder where the infused cells identify the tissues of the patient as foreign. In regard to this matter, the competitors of Kuur Therapeutics have certainly advanced by developing the required donor-consequent lymphocytes. Therefore, it can be said that Kuur Therapeutics have been falling behind due to the stagnation in the development of the cell therapy, whereas, the competitors of Kuur Therapeutics have been involved in several ongoing programs relating to the development of cell therapy (craft.co 2022).

Weaknesses

The solutions in relation to the challenges and issues of Kuur Therapeutics ltd could be provided with the help of the Ansoff Matrix Model. Following diagram can be said to signify the Ansoff Matrix Model.

 

Figure 1: Ansoff Matrix Model (Dawes 2018).

The 4 strategies in relation to the Ansoff Matrix include Market Penetration, Product Development, Market Development and Diversification. These particular strategies shall be discussed in connection to Kuur Therapeutics in order to determine the most suitable strategy in case of Kuur Therapeutics. It should be noted that out of the 4 strategies, the strategy of market penetration can be said to be the least risky, whereas the strategy relating to diversification can be said to be the riskiest.

Applying the strategy relating to the market penetration, Kuur Therapeutics should utilize its products or commodities in the present or existing market. To state it in a simple manner, Kuur Therapeutics should aim to increase the market share with the help of the strategy relating to market penetration (tractionwise.com 2022).

Kuur Therapeutics shall be able to execute the strategy relating to market penetration in several manners: –

i. Decreasing the prices in order to attract the new customers

ii. Increasing the efforts relating to promotion as well as distribution

iii. Acquiring any one of the competitors in the exact same marketplace

Therefore, Kuur Therapeutics may cater to the exact same market as well as employ a strategy relating to market penetration through the offering of the introductory prices and the increasing of the distribution and promotion efforts.

Applying the strategy relating to product development, Kuur Therapeutics should develop a new product or commodity in order to cater to or accommodate the existing market. This specific move by Kuur Therapeutics shall naturally encompass a widespread research and development as well as the expansion of its product range. It should be noted that this particular strategy relating to product development should be employed by Kuur Therapeutics only when it has a strong understanding regarding the current market and holds the ability to deliver innovative solutions for meeting the requirements of existing market (lucidchart.com 2022).

Kuur Therapeutics may implement this particular strategy in several manners: –

i. Investing in research and development in order to develop fresh new products for catering to the current or existing market

ii. Obtaining the product of a competitor as well as merging the resources in order to create a fresh new product that fulfils the requirement of existing market in a better manner

Opportunities

iii. Establishing the strategic associations or partnerships with the other firms in order to gain accessibility to the brand or distribution channels of each specific partner

Therefore, Kuur Therapeutics may modify their products in order to meet the altering requirements of the existing market. It should meet altered requirements of the existing customers.

Applying the strategy relating to market development, Kuur Therapeutics should enter any new market along with the existing or current product(s). In this regard, if Kuur Therapeutics expands into new markets, then, it shall mean expanding into the new customer segments, geographic regions and others. The strategy relating to market development strategy shall be successful only if (a) Kuur Therapeutics has the ownership of the proprietary technology with the help of which it may leverage into the specific new markets, (b) the potential and budding consumers in the specific new market are actually profitable (that is, they have the disposable income), and finally (c) the consumer behaviour in the specific new markets does not actually diverge away from the conduct or behaviour of the consumers in the current or existing markets (tractionwise.com 2022).

If Kuur Therapeutics implements the strategy relating to the market development, then such strategy might encompass any one of the ensuing approaches: –

i. Catering to a changed and distinct customer segment

ii. Entering into any new domestic market (that is, expanding regionally)

iii. Entering into any foreign market (that is, expanding internationally)

Thus, if Kuur Therapeutics wishes to enter any new market for the purposes of expansion, then, it shall offer the same commodities or products to the new demographic. 

Through the application of a diversification strategy, Kuur Therapeutics shall be able to enter a new market along with any new product or commodity. Even though this particular strategy can be said to be the riskiest (as product as well as market development are mandatory), it shall be possible to slightly mitigate the specific risk with the help of related diversification. It should be noted that the strategy relating to diversification might offer Kuur Therapeutics the greatest possibility and potential for augmented revenues, because it gives effect to a wholly new revenue stream for Kuur Therapeutics, for instance, it shall be able to access the consumer who might be spending dollars in any market that Kuur Therapeutics did not formerly have any kind of access to (lucidchart.com 2022).

Kuur Therapeutics shall be able to implement 2 kinds of diversification: –

Threats

i. Related diversification: There are possible synergies that should be realized amidst the new product/market and the existing business. Therefore, Kuur Therapeutics may pursue a related diversification strategy.

ii. Unrelated diversification: No potential or possible synergies has to be realized amidst the new product/market and the existing business. Thus, Kuur Therapeutics may pursue an unrelated diversification strategy.

The following action plan should be followed by Kuur Therapeutics: –

Objectives (List of the Team Objectives)	Tasks (What must be done in order to Accomplish the Objectives)	Success Criteria (How can Success be identified)	Time Frame (By when the Tasks should be Achieved)	Resources (What resources shall be required for each specific task)
Promote New Services or Products	Commercial Advertising should be done primarily in order to promote the services and the products. Any special introductory offer should also be used in order to promote the services and products. Another way to promote the services and the products would be to offer an exclusive preview to the loyal customers.	In this regard, success can be measured by observing that whether awareness regarding the services and products is existing or not.	1 year	§ Human resources § Digital media
Grow Digital Presence	In order to grow digital presence, Kuur Therapeutics may run any social media content. The word may also be spread with the help of sending mails. Writing a particular blog post may also increase the digital presence. In such manner, the visibility in the rankings of the search engine shall increase in the social media platforms.	In this regard, success can be measured by observing that whether digital awareness regarding the services and products is existing or not.	1 year	§ Human resources § Digital media
Lead Generation	In order to achieve the objective of lead generation, Kuur Therapeutics should make an attempt to attract the prospects to the business, thereby increasing the interest with the help of nurturing. Certain specific manners of generating leads can be said to be through the blog posts, the coupons, the live events, the job applications as well as the online content.	In this regard, success can be measured by observing that whether the client number has increased or not.	1 year	§ Human resources § Market research
Target New Customers	This specific goal or objective should be selected by Kuur Therapeutics if, even after having a loyal client base, is keen on expanding as well as reach the new clients, the customers and the audiences. This might be achieved by reaching out to the targeted customers and audiences.	In this regard, success can be measured by observing that whether customers have increased or not.	1 year	§ Human resources § Market research
Retain Existing Customers	This particular objective could be achieved by Kuur Therapeutics by focusing or emphasizing upon the already existing customers, instead of focusing upon the acquisition of new customers.	In this regard, success can be measured by observing that whether existing customers has been retained not.	1 year	§ Human resources § Market research § Research regarding customer needs
Build Brand Awareness	In order to build the brand awareness, Kuur Therapeutics may utilize the influencer marketing. Kuur Therapeutics may share content online as well as increase social involvement in order to build brand awareness. Forming a strong website presence may help in building brand awareness.	In this regard, success can be measured by observing that whether awareness regarding the brand is existing or not.	1 year	§ Human resources § Market research § Study regarding customer wants
Develop Brand Loyalty	Brand loyalty can be developed by Kuur Therapeutics if certain steps are adhered to. These steps include engaging with the customers, understanding the needs of customers, ensuring the consistency of the brand, investing in attractive logo design, making the customers return, focusing upon the best things about the brand and taking the help of the influencers for promoting the brand.	In this regard, success can be measured by observing that whether loyalty regarding the brand is existing or not.	1 year	§ Human resources § Market research § Study regarding customer wants
Increase Sales and/or Revenue	Kuur Therapeutics may increase the sales and revenue by selling the products.	In this regard, success can be measured by observing that whether sales and revenue has increased or not.	1 year	§ Human resources § Market research
Increase Profit	In order to increase profits, Kuur Therapeutics should follow certain specific steps. These steps include preparing a budget, emphasizing upon profit margins, evaluating efficacy of cost management measures, assessing business productivity, developing new business strategies as well as reducing the error rate	In this regard, success can be measured by observing that whether profits have increased or not.	1 year	§ Human resources § Market research
Expand Into a New Market	Kuur Therapeutics may expand into new markets by following certain steps, which includes reviewing the existing business model as well as target audiences, thinking about forthcoming goals for the company, researching the competitor markets, completing market research regarding the related product markets, identifying a specific target market to emphasize upon, as well as receiving feedback from the current customer-bases.	In this regard, success can be measured by observing that whether Kuur has grown in the new market or not.	1 year	§ Human resources § Market research
Grow Market Share	In order to grow the market share, Kuur Therapeutics must make an attempt to get a lor more available customers in the specific industry or the geographic location in the new area.	In this regard, success can be measured by observing that whether market share has grown or not.	1 year	§ Human resources § Market research
Build Industry Authority	In order to build the industry authority, Kuur Therapeutics should try and become the expert in connection to study or field.	In this regard, success can be measured by observing that whether industry authority is existing or not.	1 year	§ Human resources § Industry research
Quality	Kuur Therapeutics should certainly maintain the quality of the services and products that it is providing by ensuring proper production strategy.	In this regard, success can be measured by observing that whether quality is existing or not.	1 year	§ Human resources § Product research
Dependability	Kuur Therapeutics must ensure dependability of the services and products in a proper manner.	In this regard, success can be measured by observing that whether dependability upon products is existing or not.	1 year	§ Human resources § Product quality
Flexibility	Kuur Therapeutics should ensure that flexibility exists.	In this regard, success can be measured by observing that whether flexibility is existing or not.	1 year	§ Human resources

Conclusion

In conclusion, it should be noted that Kuur Therapeutics Ltd is actually committed to changing and transforming the particular lives of the patients having cancer. Kuur has been leading the progression and development in relation to the off-the-shelf ‘engineered CAR-NKT cell therapies’. Kuur Therapeutics is actually providing a very unique and compelling platform, which is believed to have the potential of producing numerous future therapies that actually targets the solid as well as the hematological tumors. This particular report has actually delivered the strategic issues, the challenges, the solutions, the implementation as well as the recommendations in relation to the above said company named Kuur Therapeutics Ltd.

Applying the strategy relating to the market penetration, Kuur Therapeutics should utilize its products or commodities in the present or existing market. To state it in a simple manner, Kuur Therapeutics should aim to increase the market share with the help of this strategy. Kuur Therapeutics shall be able to execute this strategy in several manners, which includes, decreasing the prices in order to attract the new customers, increasing the efforts relating to promotion as well as distribution, and acquiring any one of the competitors in the exact same marketplace. Therefore, Kuur Therapeutics may cater to the exact same market as well as employ the above said strategy through the offering of the introductory prices and the increasing of the distribution and promotion efforts.

References

Abou-el-Enein, M., Elsallab, M., Feldman, S.A., Fesnak, A.D., Heslop, H.E., Marks, P., Till, B.G., Bauer, G. and Savoldo, B., 2021. Scalable Manufacturing of CAR T cells for Cancer Immunotherapy. Blood cancer discovery, 2(5), p.408. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462122/

Baird, J.H., Frank, M.J., Craig, J., Patel, S., Spiegel, J.Y., Sahaf, B., Younes, S.F., Oak, J.S., Natkunam, Y., Ehlinger, Z. and Reynolds, W.D., 2020. CD22-Directed CAR T-cell therapy mediates durable complete responses in adults with relapsed or refractory large B-cell lymphoma after failure of CD19-directed CAR T-cell therapy and high response rates in adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Blood, 136, pp.28-29. https://reader.elsevier.com/reader/sd/pii/S000649711869929X?token=008A3019647722AA7269394D52ADEA7A1FC09168816DD466A09750A7DF46F0C732748E7DD1531908FDC1971AB6811832&originRegion=eu-west-1&originCreation=20220520103411

businesswire.com, 2022. Kuur Therapeutics Launches to Develop and Commercialize “Off-the-shelf” CAR-NKT Cell Therapies Targeting Hematological and Solid Tumors. [online] Businesswire.com. Available at: <https://www.businesswire.com/news/home/20200310005778/en/Kuur-Therapeutics-Launches-to-Develop-and-Commercialize-%E2%80%9COff-the-shelf%E2%80%9D-CAR-NKT-Cell-Therapies-Targeting-Hematological-and-Solid-Tumors> [Accessed 31 March 2022].

cbinsights.com, 2022. Kuur Therapeutics – Headquarter Locations, Competitors, Financials, Employees. [online] Cbinsights.com. Available at: <https://www.cbinsights.com/company/cell-medica> [Accessed 31 March 2022].

craft.co, 2022. Kuur Therapeutics competitors. [online] Craft.co. Available at: <https://craft.co/kuur-therapeutics/competitors> [Accessed 31 March 2022].

fiercebiotech.com, 2022. Cell Medica rebrands as Kuur, raises cash for CAR-NKT trials. [online] Fierce Biotech. Available at: <https://www.fiercebiotech.com/biotech/cell-medica-rebrands-as-kuur-raises-cash-for-car-nkt-trials> [Accessed 31 March 2022].

giiresearch.com, 2022. Natural Killer Cells Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026 – GII. [online] Giiresearch.com. Available at: <https://www.giiresearch.com/report/imarc1046091-natural-killer-cells-therapeutics-market-global.html> [Accessed 31 March 2022].

ipgroupplc.com, 2022. Kuur Therapeutics Ltd – Kuur Therapeutics Announces First Patients Dosed with Allogeneic CAR-NKT Cell Therapy. [online] Ipgroupplc.com. Available at: <https://www.ipgroupplc.com/media/portfolio-news/2020/2020-09-30e> [Accessed 31 March 2022].

kuurtx.com, 2022. Kuur Therapeutics – Leaders in engineered NKT cells. [online] Kuur Therapeutics. Available at: <https://www.kuurtx.com/> [Accessed 31 March 2022].

kuurtx.com, 2022. Kuur Therapeutics | Kuur Therapeutics. [online] Kuur Therapeutics. Available at: <https://www.kuurtx.com/about-us/> [Accessed 31 March 2022].

lucidchart.com, 2022. Using the Ansoff Matrix to Plan Market Strategy | Lucidchart Blog. [online] Lucidchart.com. Available at: <https://www.lucidchart.com/blog/ansoff-matrix> [Accessed 31 March 2022].

Martin, U., 2022. The Biologics News and Reports Portal. [online] pipelinereview. Available at: <https://pipelinereview.com/index.php/2021012177221/DNA-RNA-and-Cells/Kuur-Therapeutics-Announces-Interim-Clinical-Data-Supporting-CAR-NKT-Cell-Therapy-Platform.html> [Accessed 31 March 2022].

Meyer, E.H., Hoeg, R., Moroz, A., Xei, B., Wu, H.H., Pawar, R., Heydari, K., Miklos, D.B., Shiraz, P., Muffly, L.S. and Arai, S., 2020. Orca-T, a precision treg-engineered donor product, prevents acute Gvhd with less immunosuppression in an early multicenter experience with myeloablative HLA-matched transplants. Blood, 136, pp.47-48. https://reader.elsevier.com/reader/sd/pii/S0006497118695631?token=29D79DADFA86177ACF84054C0F965CA535FA5A1A293CFBB6DCFDDE6AEA882E6FA971DE2997BFAAEA4F8F2825F5ACF6EE&originRegion=eu-west-1&originCreation=20220520103118

Mo, F., Mamonkin, M., Brenner, M.K. and Heslop, H.E., 2021. Taking T-cell oncotherapy off-the-shelf. Trends in Immunology, 42(3), pp.261-272.    https://www.sciencedirect.com/science/article/abs/pii/S1471490621000041

pharmaceutical-business-review.com, 2022. Kuur Therapeutics announces first patients dosed with allogeneic CAR-NKT cell therapy – Pharmaceutical Business review. [online] Pharmaceutical Business review. Available at: <https://www.pharmaceutical-business-review.com/news/kuur-therapeutics-announces-first-patients-dosed-with-allogeneic-car-nkt-cell-therapy/> [Accessed 31 March 2022].

Quach, D.H., Ganesh, H.R., Thakkar, S., Becerra-Dominguez, L., Mehta, B., Perconti, S., Anderson, E., Hsieh, E.M., Dakhova, O., Zhang, H. and Grilley, B.J., 2020. A bank of CD30. CAR-modified, epstein-barr virus-specific T cells that lacks host reactivity and resists graft rejection for patients with CD30-positive lymphoma. Blood, 136, p.16. https://reader.elsevier.com/reader/sd/pii/S0006497118723896?token=4B80A943E724DE1543B150E94B085D7BC00E51B0CBE164999D08C1664965F49094825821CC95E33EB76BA573D0C718AB&originRegion=eu-west-1&originCreation=20220520102335

researchandmarkets.com, 2022. Ablynx NV – Strategic SWOT Analysis Review – Research and Markets. [online] Researchandmarkets.com. Available at: <https://www.researchandmarkets.com/reports/4806868/ablynx-nv-strategic-swot-analysis-review> [Accessed 31 March 2022].

techmap.uh.edu, 2022. Kuur Therapeutics | TECH Map. [online] Techmap.uh.edu. Available at: <https://techmap.uh.edu/entity/kuur-therapeutics> [Accessed 31 March 2022].

tractionwise.com, 2022. Ansoff Matrix – Strategic Growth with the Ansoff Matrix. [online] tractionwise. Available at: <https://www.tractionwise.com/en/magazine/ansoff-matrix-growth/> [Accessed 31 March 2022].